SLC5A2 and intestinal obstruction: To our knowledge, this is the first network meta-analysis to systematically evaluate intestinal obstruction risk across individual GLP-1 receptor agonists and SGLT2 inhibitors, incorporating dose-stratified nodes within each agent.